Merck KEYTRUDA QLEX approved in Japan for subcutaneous use
Merck said Japan’s MHLW approved KEYTRUDA QLEX (pembrolizumab and berahyaluronidase alfa-pmph) for subcutaneous administration for all KEYTRUDA indications approved in Japan.
Merck (NYSE: MRK), known as MSD outside the United States and Canada, said the Ministry of Health, Labor and Welfare (MHLW) in Japan has approved KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) injection for subcutaneous use for all indications approved in Japan for KEY…